ID   UD-SCC-2
AC   CVCL_E325
SY   UD-SCC 2; UD-SCC2; UDSCC-2; UDSCC2; University of Dusseldorf-Squamous Cell Carcinoma-2
DR   cancercelllines; CVCL_E325
DR   Cell_Model_Passport; SIDM00025
DR   Cosmic; 932282
DR   Cosmic; 2296311
DR   Cosmic-CLP; 1299073
DR   DepMap; ACH-002391
DR   GDSC; 1299073
DR   GEO; GSM3631261
DR   PharmacoDB; UDSCC2_1638_2019
DR   Progenetix; CVCL_E325
DR   Wikidata; Q54990107
RX   PubMed=10628319;
RX   PubMed=15495191;
RX   PubMed=16331601;
RX   PubMed=18487078;
RX   PubMed=20215515;
RX   PubMed=24201445;
RX   PubMed=25275298;
RX   PubMed=28236344;
RX   PubMed=29156801;
RX   PubMed=30894373;
RX   PubMed=31541927;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Population: Caucasian.
CC   Virology: Contains from 14 to 23 copies of the HPV16 genome (PubMed=24201445).
CC   Doubling time: 42 hours (PubMed=10628319); 4.1 days (PubMed=29156801).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg5154Gln (c.15461G>A); ClinVar=VCV000286834; Zygosity=Homozygous (PubMed=31541927).
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.2%; Native American=0%; East Asian, North=4%; East Asian, South=0%; South Asian=0%; European, North=57.49%; European, South=35.31% (PubMed=30894373).
ST   Source(s): PubMed=25275298; PubMed=29156801
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 8
ST   D16S539: 11,13
ST   D18S51: 12,17
ST   D21S11: 30,31.2
ST   D3S1358: 14,16
ST   D5S818: 10,11
ST   D7S820: 8,9
ST   D8S1179: 13,15
ST   FGA: 20,27
ST   Penta D: 9,13
ST   Penta E: 10
ST   TH01: 8,9
ST   TPOX: 8,10
ST   vWA: 15,18
DI   NCIt; C4043; Hypopharyngeal squamous cell carcinoma
DI   ORDO; Orphanet_494547; Squamous cell carcinoma of the hypopharynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=10628319;
RA   Ballo H., Koldovsky P., Hoffmann T.K., Balz V., Hildebrandt B.,
RA   Gerharz C.-D., Bier H.;
RT   "Establishment and characterization of four cell lines derived from
RT   human head and neck squamous cell carcinomas for an autologous
RT   tumor-fibroblast in vitro model.";
RL   Anticancer Res. 19:3827-3836(1999).
//
RX   PubMed=15495191; DOI=10.1002/gcc.20119;
RA   Raschke S., Balz V., Efferth T., Schulz W.A., Florl A.R.;
RT   "Homozygous deletions of CDKN2A caused by alternative mechanisms in
RT   various human cancer cell lines.";
RL   Genes Chromosomes Cancer 42:58-67(2005).
//
RX   PubMed=16331601; DOI=10.1002/ijc.21514;
RA   Muller A., Sonkoly E., Eulert C., Gerber P.A., Kubitza R.,
RA   Schirlau K., Franken-Kunkel P., Poremba C., Snyderman C.H., Klotz L.-O.,
RA   Ruzicka T., Bier H., Zlotnik A., Whiteside T.L., Homey B.,
RA   Hoffmann T.K.;
RT   "Chemokine receptors in head and neck cancer: association with
RT   metastatic spread and regulation during chemotherapy.";
RL   Int. J. Cancer 118:2147-2157(2006).
//
RX   PubMed=18487078; DOI=10.1016/j.oraloncology.2008.02.006;
RA   Hoffmann T.K., Sonkoly E., Hauser U., van Lierop A., Whiteside T.L.,
RA   Klussmann J.P., Hafner D., Schuler P., Friebe-Hoffmann U.,
RA   Scheckenbach K., Erjala K., Grenman R., Schipper J., Bier H.,
RA   Balz V.;
RT   "Alterations in the p53 pathway and their association with radio- and
RT   chemosensitivity in head and neck squamous cell carcinoma.";
RL   Oral Oncol. 44:1100-1109(2008).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=24201445; DOI=10.1101/gr.164806.113;
RA   Akagi K., Li J.-F., Broutian T.R., Padilla-Nash H.M., Xiao W.-H.,
RA   Jiang B., Rocco J.W., Teknos T.N., Kumar B., Wangsa D., He D., Ried T.,
RA   Symer D.E., Gillison M.L.;
RT   "Genome-wide analysis of HPV integration in human cancers reveals
RT   recurrent, focal genomic instability.";
RL   Genome Res. 24:185-199(2014).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=28236344; DOI=10.1002/hed.24729;
RA   Walline H.M., Goudsmit C.M., McHugh J.B., Tang A.L., Owen J.H.,
RA   Teh B.T., McKean E.L., Glover T.W., Graham M.P., Prince M.E.P.,
RA   Chepeha D.B., Chinn S.B., Ferris R.L., Gollin S.M., Hoffmann T.K.,
RA   Bier H., Brakenhoff R.H., Bradford C.R., Carey T.E.;
RT   "Integration of high-risk human papillomavirus into cellular
RT   cancer-related genes in head and neck cancer cell lines.";
RL   Head Neck 39:840-852(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//